PRESSURE POINTS: Pressure BioSciences (OTC.QB: PBIO) Squeezes Revenue Spikes Out of Life Sciences Market

PRESSURE POINTS: Pressure BioSciences (OTC.QB: PBIO) Squeezes Revenue Spikes Out of Life Sciences Market

Pressure BioSciences, Inc., a life sciences company, engages in the development and commercialization of pressure cycling technology (PCT) . PBIO  comparisions that are leaders in the industry are Thermo Fisher Scientific, Inc. (NYSE:TMO) and (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE)

Pressure BioSciences, Inc.  (OTC.QB: PBIO), currently trading at $0.30 per share with a market cap of $3.19 million, began commercial operations in mid-2007. Since then, they’ve focused on the development, marketing and sales of proprietary lab instruments and Pressure Cycling consumables. After some ups and downs and a few years of growing pains, PBI is now poised to dominate the Pressure Cycling Technology (PCT) arena.

What exactly is Pressure Cycling Technology? Well, according to PBI’s Web site, PCT is an enabling platform that “uses cycles of hydrostatic pressure between ambient (normal) and ultra-high levels (about 60,000 psi) to control bio-molecular interactions.” Sounds fairly technical and ultra-specific, doesn’t it?

Actually, it is the diversity of applications for PBI’s PCT technology that undoubtedly plays the other key role in the company’s recent commercial growth. The enhanced sample preparation systems, including an array of instruments and consumables, have increasing relevance in fields ranging from histology, vaccine development, forensics, biomarker discovery, soil biology, plant biology, bio-therapeutics characterization, and counter-bioterrorism. All in all, these fields add up to an estimated $6 billion life sciences sample preparation market – one that Pressure BioSciences intends to corner with its three Barocyclers, six application-specific reagent kits, five types of single-use processing containers, and a patent-pending sample homogenization device known as the “The Shredder SG3.”

In early May 2012, the company announced it signed a strategic co-development, co-marketing and co-selling agreement with LEAP Technologies. Under the agreement, the companies intend to develop a next-generation sample preparation system by combining Pressure’s PCT platform with LEAP’s proprietary robotics and lab automation equipment. July saw the announcement of an agreement with investors for $1.2 million to be aimed at commercializing the PCT product line. And in August, PBIO extended its reach and earning distribution total in 11 nations by signing into agreements with three companies that cover six new countries.

These momentous agreements, combined with PBIO’s careful planning and diversification potential, should snowball very soon. According to www.proactiveinvestors.com, “Total revenue for the three months that ended June 30 was $324,908 compared to $190,686 for the comparable period in 2011. Revenue from the sale of PCT products and services was $224,384 for the second quarter, up 18 per cent from a year ago. Grant revenue was $100,524, versus nil grant revenue a year earlier. The company installed eight PCT sample preparation systems during the second quarter, compared to seven during the same period in 2011. Sales of PCT-based consumables generated revenue of roughly $22,000, up from $20,000 in the second quarter of 2011.”

In addition to its ramping revenue, which the Pressure BioSciences Executive Team is driving through its growing distribution relationships, expansion of technology and company awareness, and release of new PCT products, the PBIO Team is also keeping a watchful eye on spending. That said, PBIO is getting leaner and learning how to jettison the dead weight. Operating loss narrowed by 19 percent to $682,790 and operating cash burn was down $200,000. Loss per common share – basic and diluted – was 11 cents, down from 41 cents a year ago. In addition, perhaps most importantly, PBIO overhauled its board of directors – adding two new, industry experienced members while reducing the total number from a bloated eight to a solid five.

“We believe the strong financial and operating achievements of the second quarter and year-to-date are proof that our 2012 commercialization plan has begun to bear fruit,” said Richard T. Schumacher, president and CEO of PBIO. “We further believe that this trend will continue into the second half of the year, and that we will not just surpass our reported revenue of 2011, but that we have the potential to exceed our record annual revenue of 2010 as well.”

In other words, this is one promising small cap. With its revenue spikes and growing coverage across multiple industries, investors should definitely take notice of PBIO. For more information, check out www.pressurebiosciences.com.

 

Always read full disclaimer disclosure pertaining to this article http://tomorrowsbluechips.com/disclaimer/